---
title: "Obefazimod (ABX464) in Ulcerative colitis: Mechanism of action"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Mechanism of action. Topics: Enhancer of microRNA-124 expression; Binding to the cap binding complex and splicing of a long noncoding RNA that houses miR-124; Pharmacologically active N-glucuronide metabolite acting on the same target; Downstream effects on Th17 cells, macrophages, and cytokines; 1 further topic. 5 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Enhancer of microRNA-124 expression

> “It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.”
> “If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “Obefazimod is an oral, once-daily, small molecule that increases expression of endogenous miR-124”
> “Restores immune balance while maintaining immune surveillance functions”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “With a novel mechanism of action, obefazimod is an orally available small molecule with anti-inflammatory properties through the specific and selective upregulation of miR-124 expression.”

Source: [Vermeire et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37129565/)

<a id="topic-2.1.2.6.1-2"></a>

### Binding to the cap binding complex and splicing of a long noncoding RNA that houses miR-124

> “ABX464 is a small molecule that binds to the cap binding complex (CBC)2, a complex at the 5′-end of the pre-mRNA transcript that promotes the initial interaction with transcription and processing machinery3–5.”
> “Here, using RNA CaptureSeq and deep sequencing, we report that ABX464 enhances the splicing of HIV RNA in infected PBMCs from six healthy individuals and also the expression and splicing of a single long noncoding RNA to generate the anti-inflammatory miR-124 both ex vivo and in HIV patients.”
> “While ABX464 has no effect on pre-mRNA splicing of cellular genes, depletion of CBC complex by RNAi leads to accumulation of intron retention transcripts.”
> “These results imply that ABX464 did not inhibit the function of CBC in splicing but rather strengthens it under pathological condition like inflammation and HIV infection.”

Source: [Vautrin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349857/)

<a id="topic-2.1.2.6.1-3"></a>

### Pharmacologically active N-glucuronide metabolite acting on the same target

> “Obefazimod is an investigational, oral, once-daily, small molecule that selectively enhances the expression of miR-124 and has been shown to initiate anti-inflammatory downstream effects in preclinical animal models and in humans.”
> “ABX464-N-Glu is pharmacologically active and binds, like obefazimod, to the Cap-Binding Complex (CBC) leading to enhanced expression of miR-124.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.1-4"></a>

### Downstream effects on Th17 cells, macrophages, and cytokines

> “It has been demonstrated that obefazimod enhances the expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response.”
> “In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader immunosuppression.”
> “Once expressed, micro-RNA interact with specific mRNA targets and decrease their translation into proteins to regulate specific pathways.”
> “miR-124 is known to have an effect on two key immune cells, Th17 cells and macrophages, which causes reductions in both cell populations in the gut, as well as decreases in key related cytokines such as IL-17 and IL-6.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “Enhanced expression of miR-124 reduces the expression of key cytokines (IL6r, STAT3) and chemokines (CCL2/MCP1) involved in inflammatory pathways in IBD resulting in decreased macrophage recruitment and activation and Th17 cell differentiation (13).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.1-5"></a>

### miR-124 as a modulator of inflammation: review by the discovery group

> “MiR-124 is a crucial modulator of inflammation and innate immunity that could provide therapeutic restitution of physiological pathways lost in inflammatory diseases.”
> “A recently discovered small quinoline, ABX464, was shown to upregulate miR-124 in human immune cells.”

Source: [Tazi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33387693/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
